Rupintrivir (Synonyms: AG7088)

目录号: HY-106161 纯度: 99.36%: FAQs
Data Sheet SDS COA 产品使用指南技术支持

Rupintrivirvr (AG7088)，抗病毒剂，是一种有效，选择性和不可逆的人类 rhinovirus (HRV) 3C protease 抑制剂。在 H1-Hela 和 MRC-5 细胞保护试验中，Rupintrivirvr 抑制48种不同HRV血清型的复制，平均 EC₅₀ 为 0.023 μM。Rupintrivirvr 具有免疫调节作用。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Rupintrivir Chemical Structure

CAS No. : 223537-30-2

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥3885	In-stock
1 mg	￥1300	In-stock
5 mg	￥2950	In-stock
10 mg	￥5600	In-stock
50 mg		询价
100 mg		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Rupintrivir:

Rupintrivir-d₇ 询价

MCE 顾客使用本产品发表的 5 篇科研文献

Rupintrivir 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性
纯度 & 产品资料
参考文献

生物活性

Rupintrivirvr (AG7088), an antiviral agent, is a potent, selective and irreversible inhibitor of human rhinovirus (HRV) 3C protease. Rupintrivirvr inhibits replication of a panel of 48 different HRV serotypes in H1-HeLA and MRC-5 cell protection assays, with a mean EC₅₀ of 0.023 μM. Rupintrivirvr shows immune-modulatory effect^[1]^[2].

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
H1-HeLa	EC₅₀	14 nM Compound: AG-7088	Antiviral activity against HRV14 with 3C protease T129A mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 days by XTT assay Antiviral activity against HRV14 with 3C protease T129A mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 days by XTT assay	[PMID: 17908951]
H1-HeLa	EC₅₀	14 nM Compound: AG-7088	Antiviral activity against HRV14 with 3C protease T131A mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 days by XTT assay Antiviral activity against HRV14 with 3C protease T131A mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 days by XTT assay	[PMID: 17908951]
H1-HeLa	EC₅₀	14 nM Compound: AG-7088	Antiviral activity against HRV14 with 3C protease Y139H mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 days by XTT assay Antiviral activity against HRV14 with 3C protease Y139H mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 days by XTT assay	[PMID: 17908951]
H1-HeLa	EC₅₀	140 nM Compound: AG-7088	Antiviral activity against HRV2 with 3C protease E3E/G, A103A/V, N165T mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 9 passages for 62 days by XTT assay Antiviral activity against HRV2 with 3C protease E3E/G, A103A/V, N165T mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 9 passages for 62 days by XTT assay	[PMID: 17908951]
H1-HeLa	EC₅₀	15 nM Compound: AG-7088	Antiviral activity against HRV14 with 3C protease T143P mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 days by XTT assay Antiviral activity against HRV14 with 3C protease T143P mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 days by XTT assay	[PMID: 17908951]
H1-HeLa	EC₅₀	152 nM Compound: AG-7088	Antiviral activity against HRV14 with 3C protease T129T/A, T131T/A, T143P/S mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 passages for 14 days by XTT assay Antiviral activity against HRV14 with 3C protease T129T/A, T131T/A, T143P/S mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 passages for 14 days by XTT assay	[PMID: 17908951]
H1-HeLa	EC₅₀	19 nM Compound: AG-7088	Antiviral activity against wild type HRV Hanks infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 4 days by plaque reduction assay Antiviral activity against wild type HRV Hanks infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 4 days by plaque reduction assay	[PMID: 17908951]
H1-HeLa	EC₅₀	21 nM Compound: AG-7088	Antiviral activity against wild type HRV14 infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 days by XTT assay Antiviral activity against wild type HRV14 infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 days by XTT assay	[PMID: 17908951]
H1-HeLa	EC₅₀	227 nM Compound: AG-7088	Antiviral activity against HRV14 with 3C protease T129A, T131T/A, T143P mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 4 passages for 17 days by XTT assay Antiviral activity against HRV14 with 3C protease T129A, T131T/A, T143P mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 4 passages for 17 days by XTT assay	[PMID: 17908951]
H1-HeLa	EC₅₀	24 nM Compound: AG-7088	Antiviral activity against wild type HRV39 infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 days by XTT assay Antiviral activity against wild type HRV39 infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 days by XTT assay	[PMID: 17908951]
H1-HeLa	EC₅₀	268 nM Compound: AG-7088	Antiviral activity against HRV14 with 3C protease T129A, T131A, Y139H, T143P mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 days by XTT assay Antiviral activity against HRV14 with 3C protease T129A, T131A, Y139H, T143P mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 days by XTT assay	[PMID: 17908951]
H1-HeLa	EC₅₀	30 nM Compound: AG-7088	Antiviral activity against wild type HRV2 infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 days by XTT assay Antiviral activity against wild type HRV2 infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 days by XTT assay	[PMID: 17908951]
H1-HeLa	EC₅₀	324 nM Compound: AG-7088	Antiviral activity against HRV14 with 3C protease T129A, T131A, T143P, Y139Y/H mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 10 passages for 55 days by XTT assay Antiviral activity against HRV14 with 3C protease T129A, T131A, T143P, Y139Y/H mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 10 passages for 55 days by XTT assay	[PMID: 17908951]
H1-HeLa	EC₅₀	335 nM Compound: AG-7088	Antiviral activity against HRV14 with 3C protease A121A/V, T129A, T131A, T143P, Y139Y/H mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 11 passages for 65 days by XTT assay Antiviral activity against HRV14 with 3C protease A121A/V, T129A, T131A, T143P, Y139Y/H mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 11 passages for 65 days by XTT assay	[PMID: 17908951]
H1-HeLa	EC₅₀	34 nM Compound: AG-7088	Antiviral activity against HRV2 infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 passages for 17 days by XTT assay Antiviral activity against HRV2 infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 passages for 17 days by XTT assay	[PMID: 17908951]
H1-HeLa	EC₅₀	414 nM Compound: AG-7088	Antiviral activity against HRV14 with 3C protease A121A/V, T129A, T131A, N132S, Y139Y/H, T143P mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 12 passages for 72 days by XTT assay Antiviral activity against HRV14 with 3C protease A121A/V, T129A, T131A, N132S, Y139Y/H, T143P mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 12 passages for 72 days by XTT assay	[PMID: 17908951]
H1-HeLa	EC₅₀	44 nM Compound: AG-7088	Antiviral activity against HRV2 with 3C protease N165T mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 4 passages for 24 days by XTT assay Antiviral activity against HRV2 with 3C protease N165T mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 4 passages for 24 days by XTT assay	[PMID: 17908951]
H1-HeLa	EC₅₀	51 nM Compound: AG-7088	Antiviral activity against HRV Hanks with 3C protease T130A mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 6 passages for 40 days by plaque reduction assay Antiviral activity against HRV Hanks with 3C protease T130A mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 6 passages for 40 days by plaque reduction assay	[PMID: 17908951]
H1-HeLa	EC₅₀	57 nM Compound: AG-7088	Antiviral activity against HRV2 with 3C protease N165T mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 5 passages for 30 days by XTT assay Antiviral activity against HRV2 with 3C protease N165T mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 5 passages for 30 days by XTT assay	[PMID: 17908951]
H1-HeLa	EC₅₀	67 nM Compound: AG-7088	Antiviral activity against HRV2 with 3C protease N165T mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 6 passages for 37 days by XTT assay Antiviral activity against HRV2 with 3C protease N165T mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 6 passages for 37 days by XTT assay	[PMID: 17908951]
H1-HeLa	EC₅₀	83 nM Compound: AG-7088	Antiviral activity against HRV39 with 3C protease N130NB/K, L136/F mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 5 passages for 29 days by XTT assay Antiviral activity against HRV39 with 3C protease N130NB/K, L136/F mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 5 passages for 29 days by XTT assay	[PMID: 17908951]
H1-HeLa	EC₅₀	94 nM Compound: AG-7088	Antiviral activity against HRV39 with 3C protease S105T, N130K, L136F mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 9 passages for 50 days by XTT assay Antiviral activity against HRV39 with 3C protease S105T, N130K, L136F mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 9 passages for 50 days by XTT assay	[PMID: 17908951]
H1-HeLa	EC₅₀	96 nM Compound: AG-7088	Antiviral activity against HRV14 with 3C protease T129A, T131T/A, T143P mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 5 passages for 22 days by XTT assay Antiviral activity against HRV14 with 3C protease T129A, T131T/A, T143P mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 5 passages for 22 days by XTT assay	[PMID: 17908951]
HeLa	CC₅₀	> 50 μM Compound: Rupintrivir	Cytotoxicity against human HeLa cells assessed as growth inhibition after 2 days by SRB assay Cytotoxicity against human HeLa cells assessed as growth inhibition after 2 days by SRB assay	[PMID: 30676026]
HeLa	EC₅₀	0.27 μM Compound: AG-7088	Antiviral activity against Human enterovirus CVA16 infected in human HeLa cells after 2 to 4 days by formazan dye reduction assay Antiviral activity against Human enterovirus CVA16 infected in human HeLa cells after 2 to 4 days by formazan dye reduction assay	[PMID: 19015331]
HeLa	EC₅₀	0.36 μM Compound: AG-7088	Antiviral activity against Human enterovirus Echo9 infected in human HeLa cells after 2 to 4 days by formazan dye reduction assay Antiviral activity against Human enterovirus Echo9 infected in human HeLa cells after 2 to 4 days by formazan dye reduction assay	[PMID: 19015331]
HeLa	EC₅₀	0.372 μM Compound: AG-7088	Antiviral activity against Human enterovirus CVB4 infected in human HeLa cells after 2 to 4 days by formazan dye reduction assay Antiviral activity against Human enterovirus CVB4 infected in human HeLa cells after 2 to 4 days by formazan dye reduction assay	[PMID: 19015331]
HeLa	EC₅₀	0.561 μM Compound: AG-7088	Antiviral activity against Human enterovirus EV71 infected in human HeLa cells after 2 to 4 days by formazan dye reduction assay Antiviral activity against Human enterovirus EV71 infected in human HeLa cells after 2 to 4 days by formazan dye reduction assay	[PMID: 19015331]
HeLa	EC₅₀	0.783 μM Compound: AG-7088	Antiviral activity against Human enterovirus CVB2 infected in human HeLa cells after 2 to 4 days by formazan dye reduction assay Antiviral activity against Human enterovirus CVB2 infected in human HeLa cells after 2 to 4 days by formazan dye reduction assay	[PMID: 19015331]
HeLa	EC₅₀	1.2 ng/mL Compound: Rupintrivir	Antirhinoviral activity against Human rhinovirus B infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antirhinoviral activity against Human rhinovirus B infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 24900468]
HeLa	EC₅₀	1.2 ng/mL Compound: Rupintrivir	Antirhinoviral activity against antiviral-resistant Human rhinovirus A infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antirhinoviral activity against antiviral-resistant Human rhinovirus A infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 24900468]
HeLa	EC₅₀	1.247 μM Compound: AG-7088	Antiviral activity against Human enterovirus CVB1 infected in human HeLa cells after 2 to 4 days by formazan dye reduction assay Antiviral activity against Human enterovirus CVB1 infected in human HeLa cells after 2 to 4 days by formazan dye reduction assay	[PMID: 19015331]
HeLa	EC₅₀	1.5 ng/mL Compound: Rupintrivir	Antirhinoviral activity against major receptor-resistant Human rhinovirus infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antirhinoviral activity against major receptor-resistant Human rhinovirus infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 24900468]
HeLa	EC₅₀	2 ng/mL Compound: Rupintrivir	Antirhinoviral activity against Human rhinovirus A infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antirhinoviral activity against Human rhinovirus A infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 24900468]
HeLa	EC₅₀	2 ng/mL Compound: Rupintrivir	Antirhinoviral activity against antiviral-resistant Human rhinovirus B infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antirhinoviral activity against antiviral-resistant Human rhinovirus B infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 24900468]
HeLa	EC₅₀	3 ng/mL Compound: Rupintrivir	Antirhinoviral activity against minor receptor-resistant Human rhinovirus infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antirhinoviral activity against minor receptor-resistant Human rhinovirus infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 24900468]
RD	EC₅₀	0.009 μM Compound: 2H; AG7088	Antiviral activity against Enterovirus 71/Shenzhen/120F1/09 infected in human RD cells assessed as reduction in virus induced cell death after 72 hrs by CCK-8 assay Antiviral activity against Enterovirus 71/Shenzhen/120F1/09 infected in human RD cells assessed as reduction in virus induced cell death after 72 hrs by CCK-8 assay	[PMID: 27234148]
Vero	CC₅₀	> 50 μM Compound: Rupintrivir	Cytotoxicity against African green monkey Vero cells assessed as growth inhibition after 2 days by SRB assay Cytotoxicity against African green monkey Vero cells assessed as growth inhibition after 2 days by SRB assay	[PMID: 30676026]
Vero	EC₅₀	0.419 μM Compound: AG-7088	Antiviral activity against Human enterovirus CVA16 infected in Vero cells after 4 to 7 days by plaque reduction assay Antiviral activity against Human enterovirus CVA16 infected in Vero cells after 4 to 7 days by plaque reduction assay	[PMID: 19015331]
Vero	EC₅₀	0.481 μM Compound: AG-7088	Antiviral activity against Human enterovirus Echo9 infected in Vero cells after 4 to 7 days by plaque reduction assay Antiviral activity against Human enterovirus Echo9 infected in Vero cells after 4 to 7 days by plaque reduction assay	[PMID: 19015331]
Vero	EC₅₀	0.791 μM Compound: AG-7088	Antiviral activity against Human enterovirus EV71 infected in Vero cells after 4 to 7 days by plaque reduction assay Antiviral activity against Human enterovirus EV71 infected in Vero cells after 4 to 7 days by plaque reduction assay	[PMID: 19015331]
Vero	EC₅₀	0.843 μM Compound: AG-7088	Antiviral activity against Human enterovirus CVB4 infected in Vero cells after 4 to 7 days by plaque reduction assay Antiviral activity against Human enterovirus CVB4 infected in Vero cells after 4 to 7 days by plaque reduction assay	[PMID: 19015331]
Vero	EC₅₀	0.982 μM Compound: AG-7088	Antiviral activity against Human enterovirus CVB2 infected in Vero cells after 4 to 7 days by plaque reduction assay Antiviral activity against Human enterovirus CVB2 infected in Vero cells after 4 to 7 days by plaque reduction assay	[PMID: 19015331]
Vero	EC₅₀	1.725 μM Compound: AG-7088	Antiviral activity against Human enterovirus CVB1 infected in Vero cells after 4 to 7 days by plaque reduction assay Antiviral activity against Human enterovirus CVB1 infected in Vero cells after 4 to 7 days by plaque reduction assay	[PMID: 19015331]

体外研究
(In Vitro)

在 H1-HeLa 和 MRC-5 细胞保护试验中，Rupintrivirvr (AG7088) 抑制所有 HRV 血清型 (48 种中的 48 种) 的复制，平均 50% 有效浓度 (EC₅₀) 为 0.023 μM 和平均 EC₉₀ 为 0.082 μM 以及相关的小核糖核酸病毒，包括柯萨奇病毒 A21 和 B3、肠道病毒 70 和埃可病毒 11^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Rupintrivirvr (AG7088) 减少离体 HDM 致敏小鼠精密切割肺切片 (PCLS) 中 RV 诱导的 TH-2 细胞因子 IL-4^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

598.66

Formula

C₃₁H₃₉FN₄O₇

CAS 号

223537-30-2

性状

固体

颜色

White to off-white

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

细胞实验：

DMSO 中的溶解度 : 50 mg/mL (83.52 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.6704 mL	8.3520 mL	16.7040 mL
5 mM	0.3341 mL	1.6704 mL	3.3408 mL
10 mM	0.1670 mL	0.8352 mL	1.6704 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 1.67 mg/mL (2.79 mM); 澄清溶液

此方案可获得 ≥ 1.67 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 16.7 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.91%

选择批次：

Data Sheet (630 KB) SDS (251 KB)

COA (265 KB) LCMS (259 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Patick AK, et al. In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother. 1999 Oct;43(10):2444-50. [Content Brief]

[2]. Danov O, et al. Rupintrivir reduces RV-induced TH-2 cytokine IL-4 in precision-cut lung slices (PCLS) of HDM-sensitized mice ex vivo. Respir Res. 2019 Oct 22;20(1):228. [Content Brief]

[3]. Dragovich PS, et al. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 3. Structure-activity studies of ketomethylene-containing peptidomimetics. J Med Chem. 1999 Apr 8;42(7):1203-12. [Content Brief]

Rupintrivir 相关分类

Inflammation/Immunology Infection

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.6704 mL	8.3520 mL	16.7040 mL	41.7599 mL
	5 mM	0.3341 mL	1.6704 mL	3.3408 mL	8.3520 mL
	10 mM	0.1670 mL	0.8352 mL	1.6704 mL	4.1760 mL
	15 mM	0.1114 mL	0.5568 mL	1.1136 mL	2.7840 mL
	20 mM	0.0835 mL	0.4176 mL	0.8352 mL	2.0880 mL
	25 mM	0.0668 mL	0.3341 mL	0.6682 mL	1.6704 mL
	30 mM	0.0557 mL	0.2784 mL	0.5568 mL	1.3920 mL
	40 mM	0.0418 mL	0.2088 mL	0.4176 mL	1.0440 mL
	50 mM	0.0334 mL	0.1670 mL	0.3341 mL	0.8352 mL
	60 mM	0.0278 mL	0.1392 mL	0.2784 mL	0.6960 mL
	80 mM	0.0209 mL	0.1044 mL	0.2088 mL	0.5220 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

Rupintrivir (Synonyms: AG7088)

Customer Review

Other Forms of Rupintrivir:

MCE 顾客使用本产品发表的 5 篇科研文献

Rupintrivir 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Rupintrivir 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Rupintrivir (Synonyms: AG7088)

Customer Review

Other Forms of Rupintrivir:

Rupintrivir 相关抗体

MCE 顾客使用本产品发表的 5 篇科研文献

Rupintrivir 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性

纯度 & 产品资料

参考文献

Rupintrivir 相关抗体:

摩尔计算器

稀释计算器

Rupintrivir 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z